| Identification | Back Directory | [Name]
ceralifimod | [CAS]
891859-12-4 | [Synonyms]
ONO-4641
ceralifimod
Ceralifimod (ONO-4641)
Ceralifimod (Synonyms: ONO-4641)
3-Azetidinecarboxylic acid, 1-[[3,4-dihydro-6-[(2-methoxy-4-propylphenyl)methoxy]-1-methyl-2-naphthalenyl]methyl]- | [Molecular Formula]
C27H33NO4 | [MDL Number]
MFCD28502037 | [MOL File]
891859-12-4.mol | [Molecular Weight]
435.56 |
| Chemical Properties | Back Directory | [Boiling point ]
595.9±50.0 °C(Predicted) | [density ]
1.172±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:5.0(Max Conc. mg/mL);11.48(Max Conc. mM) | [form ]
A crystalline solid | [pka]
2.71±0.20(Predicted) |
| Hazard Information | Back Directory | [Description]
Ceralifimod is an agonist of the sphingosine-1-phosphate (S1P) receptors S1P1 and S1P5 (Kis = 0.626 and 0.574 nM, respectively). It is selective for S1P1 and S1P5 over S1P2-4 (Kis = >5,450, >5,630, and 28.8 nM, respectively). Ceralifimod induces calcium influx in CHO-K1 cells overexpressing S1P1 (EC50 = 1 nM) and cAMP accumulation in CHO-K1 cells overexpressing S1P1 or S1P5 (EC50s = 0.027 and 0.33 nM, respectively). In vivo, ceralifimod (0.03 and 0.1 mg/kg) reduces paw edema in a rat model of collagen induced arthritis (CIA). It also delays disease onset and inhibits lymphocyte infiltration of the spinal cord in a rat model of experimental autoimmune encephalomyelitis (EAE) and prevents disease relapse in a non-obese diabetic mouse model of relapsing-remitting EAE. | [storage]
Store at -20°C |
|
|